- Dramatically expands IP portfolio of cannabinoid
synthesis related genes and enzymes
- Tackles known enzymatic and modification bottlenecks and
challenges in biosynthesis
TEL
AVIV, Israel, Aug. 11,
2022 /PRNewswire/ -- Xinteza API Ltd., an
innovative biosynthesis technology company, announced today that it
has expanded its IP portfolio with a breakthrough discovery of a
novel, non-cannabis plant-derived production system, which is
capable of highly efficient and flawless end-to-end cannabinoid
synthesis. The company's IP portfolio is based on a license signed
with Yeda, the commercial arm of the Weizmann Institute of
Science.
Unlike Cannabis Sativa, which only produces cannabinoids in its
female flowering parts, the novel expression system contains
cannabinoid enzymatic machinery throughout its entire botanical
tissue mass, and thus has the potential to yield a higher
active-ingredient-to-biomass ratio than cannabis plants.
"This discovery is a major milestone in the path to uncover and
exploit rare and new cannabinoid molecules with potentially novel
pharmacological activities," said Prof. Asaph Aharoni, Xinteza's Scientific Co-Founder
and Head of the Weizmann Institute of Science Plant Metabolomics
Lab and of the Institute's Plant and Environmental Sciences
Department. "Moreover, this alternative non-Cannabaceae production
system is significantly more amenable than cannabis to genetic
engineering and cellular transformation, allowing greater
flexibility in a range of biosynthesis enhancement and optimization
processes," added Prof. Aharoni.
Biosynthesis technologies have the potential to revolutionize
cultivation-and-extraction-based production methods of cannabinoid
compounds for CPG and pharma. However, the development of these
long-awaited cannabinoid biosynthesis processes has been slowed
down and challenged by several enzymatic and genetic
modification-related bottlenecks arising from the introduction of
cannabis genes into microorganism-based fermentation systems. The
discovery of a non-Cannabaceae cannabinoid-producing botanical
expression system has the potential to solve and mitigate some of
these problems by initiating a novel toolkit of genes and enzymatic
machinery. By utilizing this new toolkit, Xinteza aims to design
novel pathways for cannabinoid biosynthesis, in order to achieve
higher yields and efficiencies, better consistency, purity, and
cost effectiveness.
"This revolutionary discovery places Xinteza at the forefront of
cannabinoid sourcing and synthesis and is creating excitement in
the field" says Alon Gal, CEO of
Xinteza API. "The flexibility and efficacy of this extraordinary
patent-pending alternative genetic system offers solutions to some
of the burning delivery issues currently plaguing our
industry. We will continue to advance our research and
development of the most innovative and powerful biosynthesis of an
array of high-value cannabinoids and to leverage our fast-growing
library of genes, enzymes, and novel molecules, while advancing
collaborations with leading players in the biosynthesis arena."
About Xinteza API
Xinteza API Ltd. is engaged in the research and discovery of a
wide array of new genes and ultra-novel genetic pathways for the
biosynthesis of cannabinoids and psychoactive ingredients, and the
development of their bio-production methods. Xinteza holds an
exclusive license for both cannabinoids and psychoactives from the
Weizmann Institute of Science with research led by Prof.
Asaph Aharoni and is diligently
building an unprecedented portfolio of dozens of related IP assets
and patents.
Founded in 2019 and led by a team of experienced entrepreneurs,
Xinteza's strategic partners include industry players such as IM
Cannabis (NASDAQ: IMCC)(CSE: IMCC)
Xinteza's goal is to produce a large array of natural lab made
minor and modified cannabinoids, and the most sought-after
psychoactive ingredients. It focuses on making the production of
innovative APIs and AIs for high end CPG and pharma more accessible
by implementing its disruptive discoveries of novel genes, genetic
pathways, and molecules, and by removing bottlenecks and boosting
natural production processes.
About Yeda
Yeda Research and Development Company Ltd. is the commercial arm
of the Weizmann Institute of Science. Yeda currently manages
approximately 500 unique patent families and has generated the
highest income per researcher compared to any other academic
technology transfer operation worldwide. Through the years, Yeda
has contributed the commercialization of a number of groundbreaking
therapies, such as Copaxone, Rebif, Tookad®, Erbitux®, Vectibix®,
Protrazza®, Humira®, and recently the CAR-T cancer therapy
Yescarta®.
About the Weizmann Institute of Science
The Weizmann Institute of Science in Israel is one of the world's top-ranking
multidisciplinary research institutions. Noted for its wide-ranging
exploration of the natural and exact sciences, Weizmann Institute's
scientists are advancing research on the human brain, artificial
intelligence, computer science and encryption, astrophysics and
particle physics, and are tackling diseases such as cancer, while
also addressing climate change through environmental, ocean, and
plant sciences.
For additional information,
visit: https://xinteza.com or visit our
official LinkedIn Channel.
or contact:
Xinteza API Ltd. – Press, MarCom, Investor
Relations
E: info@xinteza.com
Alon Gal, CEO and
co-founder
E: alon@xinteza.com
Dr. Zohar Koren, CTO and
co-founder
E:
zohar@xinteza.com
Photo -
https://mma.prnewswire.com/media/1876584/Alon_Gal_Xinteza_API_Ltd.jpg
Photo -
https://mma.prnewswire.com/media/1876676/Prof_Asaph_Aharoni_Weizmann.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/xinteza-unveils-disruptive-non-cannabaceae-source-for-cannabinoid-biosynthesis-in-breakthrough-research-led-by-prof-asaph-aharoni-at-the-weizmann-institute-of-science-301604375.html
SOURCE Xinteza API Ltd.